The pharmacodynamics of telavancin and vancomycin were compared using 25 neutropenic murine thigh and lung infection models. Four S. aureus strains were 26 
Introduction 46
Telavancin (TD-6424) is a semisynthetic lipoglycopeptide with enhanced gram-47 positive activity including multi-drug resistant gram-positive organisms (1). Telavancin 48 has a dual mechanism of action targeting both peptidoglycan synthesis and cell 49 membrane function, which is purported to be responsible for its improved bactericidal 50 activity compared to vancomycin (2, 3) . Efficacy has been demonstrated in clinical trials 51 in patients with complicated skin and skin structure infection (cSSSI) and hospital 52 acquired pneumonia (HABP/VABP) due to gram-positive pathogens (4, 5) . 53 Subsequently, telavancin also demonstrated efficacy in treating patients with either 54 cSSSI and for patients with HABP/VABP who had concurrent S. aureus bacteremia (6) . 55
Pre-clinical pharmacodynamic models are critical components in optimizing 56
dosing regimen design and setting susceptibility breakpoints (7). Numerous in vivo 57 studies with telavancin have been performed demonstrating promising activity (8); 58 however, pharmacodynamic analyses are sparse (9). Therefore, the following studies 59
were designed to characterize the in vivo PK/PD characteristics of telavancin and 60 vancomycin in the neutropenic murine thigh and lung infection models. Studies included 61 those designed to identify the magnitude of the PK/PD index required for efficacy 62 among multiple S. aureus isolates, including beta-lactam resistant and vancomycin-63 The dose-response data was then modeled utilizing both plasma and ELF PK 141 data. The relationship between telavancin plasma total drug 24 h AUC/MIC and 142 therapeutic effect in the thigh and lung model is shown in Figure 5a -b. The data fit after 143 applying the Hill Emax model to the plasma 24 h AUC/MIC and treatment effect data 144 was fairly robust for each infection site (R 2 = 0.85 for thigh and R 2 = 0.91 for lung). 145
Similar to the dose-response curves, the AUC/MIC exposures associated with stasis or 146 cidal activity were shifted to the left (i.e. smaller) for the lung model in comparison to the 147 thigh model. Additionally, the slope of the curve was steeper in the lung model 148 indicating more cidal activity was observed with incremental increases in AUC/MIC 149 exposure. ELF pharmacokinetic data for telavancin was also modelled and the 150 relationship between ELF total drug 24 h AUC/MIC and therapeutic effect in the lung 151 model is shown in Figure 6a . As expected, the best-fit line based on Hill equation from 152 ELF analyses was almost identical to that of plasma AUC/MIC. However, as only ~4% 153 of plasma drug penetrated into the ELF, the ELF AUC/MIC was proportionally lower 154 compared to plasma AUC/MIC targets. The same relationship between vancomycin 155 plasma 24 h AUC/MIC and treatment outcome was examined for both models and 156 shown in Figure 7a -b. The relationship between AUC/MIC and therapeutic effect was8 respectively. ELF pharmacokinetic data for vancomycin modelled to 24 h ELF 159 AUC/MIC and therapeutic effect in the lung is shown in Figure 6b . 160
The plasma AUC/MIC values associated with the stasis and 1 log kill endpoints 161
were calculated for each strain in each infection site and are shown in Table 3 for 162 telavancin and Table 4 for vancomycin. Both plasma total and free drug concentrations 163 were considered. The telavancin mean 24 h plasma free drug AUC/MIC for stasis was 164 83 and 40.4 for the thigh and lung, respectively (P = 0.22). The telavancin mean 24 h 165 plasma free drug AUC/MIC associated with 1 log kill was 215 and 76.4 for the thigh and 166 lung models, respectively (P = 0.15). In the case of vancomycin, the mean 24 h plasma 167 free drug AUC/MIC for stasis was 77.9 and 45.3 for the thigh and lung, respectively (P = 168 0.34). The vancomycin mean 24 h plasma free drug AUC/MIC associated with 1 log kill 169 was 282 and 113 for the thigh and lung, respectively (P = 0.19). Free plasma AUC/MIC 170 targets were similar comparing telavancin to vancomycin for each endpoint and 171 infection site (P-value range from 0.55 to 0.88). 172
The ELF 24 h AUC/MIC targets in the lung model are shown in Table 5 for each 173 isolate for telavancin and vancomycin. The mean ELF 24 h AUC/MIC associated with 174 net stasis and 1 log kill for telavancin was 32.4 and 60.8, respectively. The mean ELF 175 24 h AUC/MIC associated with net stasis and 1 log kill for vancomycin was 50.8 and 176
92.0, respectively. While numerically lower for telavancin than vancomycin, the target 177 AUC/MIC exposures were not statistically different between the two drugs (P = 0.89 and 178 P = 0.51, respectively). These values are similar to targets identified for another lipoglycopeptide, dalbavancin, 208 using the same infection model and methods of PD analyses (12, 13) . The telavancin 209 exposure-response relationships were relatively steep such that 1 log 10 kill endpoints 210 were in general achieved with an approximate 2-fold increase in AUC/MIC exposure. 211
These targets are particularly robust given we utilized multiple strains with a range of in 212 vitro susceptibility to telavancin to generate the estimates. Additionally, we were able to 213 compare the pharmacodynamic activity of telavancin to that of vancomycin, which in 214 many settings remains the gold standard therapy for serious MRSA infection including 215 pneumonia. The pharmacodynamic activity and target exposures associated with stasis 216 and cidal endpoints for telavancin in each infection site were very similar to those of 217
vancomycin. 218
An important consideration in PK/PD studies is accounting for protein binding of 219 drug as it is generally accepted only free drug is available for antimicrobial activity at the 220 site of infection (16, 17) . In the current studies, when plasma total drug AUC/MIC 221 targets are compared between telavancin and vancomycin, it would appear that 222 significant differences occur as the telavancin plasma total drug AUC/MIC targets are 223 10-to 20-fold higher than vancomycin. However, plasma free drug AUC/MIC targets are 224 congruent. Protein binding also appears to impact the ELF pharmacokinetics of each 225 drug. Again, it would appear that there are significant differences between drugs as 226 which is equivalent to the proportion of free drug in plasma based on protein binding of 231 96%. The same held true for vancomycin, where we observed 70-80% penetration into 232 ELF, which approximates the proportion of free drug that would be expected in the 233 plasma based on protein binding of 25%. Thus, the penetration into ELF for both drugs 234 is approximately 100% of the free plasma fraction. Based on this, it is not surprising we 235 found PK/PD targets using total drug ELF AUC/MIC to closely approximate the plasma 236 free drug AUC/MIC targets for each drug in the lung infection model. An interesting observation in our study was a shift to the left for the exposure-261 response curves in the lung infection model compared to the thigh infection model, 262 indicating less drug was needed to achieve similar outcomes. This resulted in static 263 doses, 1 log kill doses, and AUC/MIC targets associated with these endpoints which are 264 approximately 2-fold larger for the thigh model than the lung model; however, these 265 differences were not statistically significant. There are important considerations 266 associated with observed differences in exposure-response relationships between 267 different infection models. Two very relevant factors are the initial burden of organism 268 in each model and the ability of the organism to grow and produce infection over time in 269 untreated animals (i.e. fitness). While the infection burden at the start of therapy were 270 remarkably congruent, we did note consistently lower growth in the untreated control 271 mice in the murine lung model compared to the thigh model which was statistically 272 significant (P <0.001). Thus, we feel the differences in the ability of the organism to Thus, the PD targets associated with efficacy identified in this study and human PK data 287 suggests that telavancin would be predicted to be effective against nearly all S. aureus 288
isolates. 289
In conclusion, these studies demonstrate that telavancin exhibits dose- Importantly, for telavancin the 1 log kill targets identified in these studies, 298 epidemiological susceptibility surveys, and human PK data suggest that the current 299 dosing regimen in humans would be predicted to provide telavancin exposures that are 300 sufficient to achieve optimal efficacy. Additionally, the proposed breakpoint of ≤0.12 301 mg/L appears appropriate based on these studies. In total, these findings support 302 telavancin as efficacious option with PK/PD exposures optimized for serious S. aureus 303 infections including MRSA pneumonia. 304
305

MATERIALS AND METHODS 306
Organisms, media, and antibiotic 307
Four Staphylococcus aureus strains were used for these studies, including 1 308 methicillin-susceptible (MSSA) and 3 methicillin-resistant (MRSA) strains (Table 1) fresh MHB, bacterial counts of the inoculum were 7.0 ± 0.1 log 10 CFU/ml and 6.7 ± 0.1 334 log 10 CFU/ml for telavancin and vancomycin in the thigh infection model. Infection with 335 each of the isolates was produced by injection of 0.1 ml of inoculum into the thigh of 336 isofluorane-anesthetized (32). Four thigh infections were included in each treatment and 337 control group. In the lung infection model, bacterial counts of the inoculum were 7.7 ± 338 0.1 log 10 CFU/ml and 7.8 ± 0.1 log 10 CFU/ml for telavancin and vancomycin, 339 respectively. Lung infection was produced with each isolate by pipetting 50 μl of 340 inoculum into the anterior nares of isofluorane-anesthetized mice held upright to allow 341 for inhalation into the lungs (32). Three mice were included in each treatment and 342 on June 16, 2017 by Univ of Wisconsin -Madison http://aac.asm.org/ Downloaded from control group. Drug treatment was commenced two hours after infection was induced. 343
Treatment duration was 24 h, at which time mice were euthanized by CO 2 asphyxiation 344 and the thighs or lungs were aseptically harvested for CFU determination by serial 345 plating on MHB. 346 347
Drug pharmacokinetics 348
Single dose plasma pharmacokinetics of telavancin and vancomycin were 349 studied in mice. Animals were administered a single subcutaneous dose (0.2 ml/dose) 350 at dose levels of 1.25, 5, 20 and 80 mg/kg. Groups of three mice were sampled at each 351 time point and dose level. There were 7 sampling times that ranged from 0.5 to 12 h. and 25% was used to determine free drug fraction for vancomycin (9, 34) . 366
Single-dose ELF pharmacokinetics were also determined for the same doses 367 and time points as those listed above for each drug. Bronchial alveolar lavage (BAL) 368 fluid was obtained by instillation of 1 ml of sterile saline into the lungs of each animal 369 followed by immediate removal. The BAL fluid was centrifuged to remove blood and 370 cellular debris. Supernatant was then collected, immediately frozen and stored at -70° 371 
Pharmacodynamic target determination 378
Neutropenic mice were infected with one of four S. aureus strains as described 379 above. Both thigh and lung infection models were utilized for all strains. Treatment with 380 telavancin or vancomycin was initiated 2 h after infection. Five total doses of telavancin, 381 which ranged from 1.25 to 320 mg/kg/24 h, were fractionated into 6-hourly dosing 382 regimens. Similarly, seven total doses of vancomycin, which ranged from 1.25 to 5120 383 mg/kg/24 h, were fractionated into 6-hourly dosing regimens. The drug doses were 384 administered subcutaneously. Mice were euthanized after 24 h and the infected thighs 385 or lungs were aseptically removed and processed for CFU determination. Dose-386 on June 16, 2017 by Univ of Wisconsin -Madison http://aac.asm.org/ Downloaded from response curves were generated for telavancin and vancomycin from the treatment data 387
for both infection models. 388
Pharmacodynamic analyses utilized data from the PK study, in vitro susceptibility 389 results, and the treatment outcome data. The PK/PD 24-hour AUC/MIC ratio was used 390 for all analyses as this has been the pharmacodynamically linked index in previous 391 glycopeptide, lipopeptide and lipoglycopeptide studies (8, 9, 12, 15, (35) (36) (37) . The 392 correlation between treatment efficacy and AUC/MIC was determined by nonlinear 393 least-squares multivariate regression (Sigma Plot version 12.3; Systat Software, San 394
Jose, CA). The model is derived from the Hill equation:
where E is the effect or, in this case, the log change in CFU per thigh between treated 396 mice and untreated controls after the 24 h period of study, Emax is the maximum effect, 397 D is the 24 h total dose, ED50 is the dose required to achieve 50% of Emax, and N is 398 the slope of the dose-effect curve. The indices Emax, ED50, and N were calculated 399 using nonlinear least-squares regression. A sigmoid dose-response Emax model 400 derived from the four-parameter Hill equation was used to calculate the dose of 401 telavancin or vancomycin that produced a net bacteriostatic and 1 log 10 kill endpoints 402 over 24 h (static and 1 log kill doses). Pharmacodynamic target AUC/MIC for each 403 endpoint and for each isolate were determined using total plasma, free plasma, and 404 total ELF drug concentrations. The PD targets identified in the thigh and lung models 405 were compared by T-test or Mann Whitney Rank Sum to determine if significant 406 differences existed between infection sites or between each of the drugs at the same 407 site. 408
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EUCAST. route starting two hours after infection. After 24 hours, mice were euthanized and thigh 579 or lung organs were aseptically harvested, homogenized, and serially plated to 580 determine CFU burden. Each point in the thigh model represents the mean and 581 standard deviation from four thigh replicates and each point in the lung model 582 represents the mean and standard deviations from three lung replicates. The dashed 583 horizontal line represents the burden at the start of therapy. Points above the line 584 represent net growth whereas those below represent killing (cidal) activity. 585 586 Figure 4 . Vancomycin dose-response curves in the thigh (A) and lung (B) infection 587 models. Groups of mice were infected with each S. aureus strain and treatment 588 commenced with one of 7 different dosing regimens of telavancin by subcutaneous 589 route starting two hours after infection. After 24 hours, mice were euthanized and thigh 590 or lung organs were aseptically harvested, homogenized, and serially plated to 591 determine CFU burden. Each point in the thigh model represents the mean and 592 standard deviation from four thigh replicates and each point in the lung model 593 represents the mean and standard deviations from three lung replicates. The dashed 594 horizontal line represents the burden at the start of therapy. Points above the line 595 represent net growth whereas those below represent killing (cidal) activity. 596 597 Figure 5 . Relationship between telavancin plasma 24 h total drug AUC/MIC and 598 treatment outcome in the thigh (A) and lung (B) infection models. Each point in the thigh 599 model represents the mean from four thigh replicates and each point in the lung model 600 represents the mean from three lung replicates. The dashed horizontal line represents 601 the burden at the start of therapy. Points above the line represent net growth whereas 602 those below represent killing (cidal) activity. The curved line represents the best-fit line 603 based on the sigmoid Emax Hill equation. Also shown is the maximum effect (Emax), 604 AUC/MIC associated with 50% maximal effect (ED50), slope of the best-fit line (N), and 605 nonlinear least-squares multivariate regression analysis (R 2 ). 606 607
